Abstract:

AIM: To compare the efficacy and safety between irinotecan (CPT) and topotecan (TPT) combined with nedaplatin (NDP) in the treatment of extensive small cell lung cancer.  METHODS: Eighty-nine cases of patients who have been diagnosed as extensive small cell lung cancer were analyzed, in which 44 cases received CPT+NDP while the other 45 cases received TPT+NDP as chemotherapy. Three weeks are one treatment course, every patient in two groups accepted more than 2 periods of chemotherapy. On the first day of each course, they received intravenous drip with LBP 30 mg/m2. In addition, CPT+NDP group was given intravenous drip with NDP 80 mg/m2 on the first day and CPT 60 mg/m2 on the first eighth, fifteenth day, while TPT+NDP group was given intravenous drip with NDP 80 mg/m2 on the first day and TPT 1.2 mg/m2 on the first to fifth day. Comparison was made between the clinical response rate (RR), disease control rate (DCR), median overall survival, median progression-free survival and adverse reactions between the two groups. RESULTS:The RR of the two groups were 36.36% and 37.78%, the CDR of the two groups were 72.73%and 66.67%. There was no significant differences between the two groups (P>0.05). The median overall survival of the two groups were 12.0 months and 11.2 months, the median progression-free survival were 6.5 months and 5.8 months weeks, there are also no differences between the two groups (P>0.05). The CPT+NDP group was milder than the TPT+NDP group in the leukopenia and the thrombopenia (P<0.05), while more severe than the TPT group in the diarrhea and neutrophilic (P<0.05). CONCLUSION: The curative effect of CPT combined with NDP is similar with the TPT combined with NDP on the treatment of extensive small cell lung cancer patients. The main adverse reaction of the former one is diarrhea and neukopenia, while the latter one is leukopenia and thrombopenia. Therapeutic regimen should be chosen according to the patients' physical condition.

Key words: irinotecan, topotecan, nedaplatin, efficacy, adverse reaction